Loading patent…
AssigneeWhitehead Institute for Biomedical Research
InventorsDohoon Kim, David M. Sabatini, Richard Possemato
Estimating the term…
In some aspects, methods of inhibiting survival or proliferation of a tumor cell are provided, the methods comprising inhibiting the glycine cleavage system (GCS) of the tumor cell. In some aspects, methods of treating a subject in need of treatment for a tumor, the method comprising inhibiting the GCS in the tumor. In some embodiments, the methods comprise contacting a tumor cell or tumor with a GCS inhibitor. In some embodiments, the tumor cell or tumor has elevated expression of serine hydroxymethyltransferase 2 (SH1VIT2). In some aspects, methods of identifying a tumor cell or tumor that is sensitive to inhibiting the GCS are provided, the methods comprising determining whether the tumor cell or tumor overexpresses SHMT2. In some aspects, methods of identifying a candidate anti-cancer agent are provided, the methods comprising identifying or modifying a GCS inhibitor.
A method of inhibiting proliferation or survival of a tumor cell, the method comprising contacting the cell with an inhibitor of the glycine cleavage system (GCS).
A method of inhibiting proliferation or survival of a cell that overexpresses SHMT2, the method comprising contacting the cell with an inhibitor of the GCS.
A method of identifying a candidate anti-tumor agent, the method comprising determining whether a test agent binds to or inhibits a GCS component or inhibits the GCS, wherein if the test agent binds to or inhibits a GCS component or inhibits the GCS, the test agent is identified as a candidate anti-tumor agent.
A method of identifying an anti-tumor agent, the method comprising (a) contacting a tumor cell, tumor cell line, or tumor with a GCS inhibitor;
A method of predicting the likelihood that a tumor, tumor cell, or tumor cell line is sensitive to GCS inhibition, the method comprising;
A method of identifying a tumor cell or tumor that has an increased likelihood of being sensitive to GCS inhibition, the method comprising assessing expression of SHMT2 in the tumor cell or tumor, wherein if the tumor cell or tumor overexpresses SHMT2, the tumor cell or tumor has an increased likelihood of being sensitive to GCS inhibition than if SHMT2 is not overexpressed.
A method of determining whether a subject in need of treatment for a tumor is a suitable candidate for treatment with a GCS inhibitor, the method comprising determining whether the tumor overexpresses SHMT2 or is of a tumor type that has a tendency to overexpress SHMT2, wherein if the tumor overexpresses SHMT2 or is of a tumor type that has a tendency to overexpress SHMT2, the subject is a suitable candidate for treatment with a GCS inhibitor.
A method of selecting a therapeutic agent for a subject in need of treatment for a tumor, the method comprising:
A method of treating a subject in need of treatment for a tumor, the method comprising:
A method of treating a subject in need of treatment for a tumor, the method comprising:
A method of monitoring a subject in need of treatment for a tumor, the method comprising:
A pharmaceutical composition for anti-tumor therapy, comprising:
A unit dosage form comprising a GCS inhibitor in an amount appropriate for administration to a subject for treatment of a tumor.
A composition comprising:
A kit comprising:
Dependencies are inferred from the claim text.